News | Breast Imaging | July 09, 2020

When and How to Monitor for Breast Cancer After Childhood Chest Radiation

Simulation finds starting at age 30 with MRI and mammography to be the preferred strategy; starting at 25 prevented marginally more deaths, but with more testing and emotional stress

Simulation finds starting at age 30 with MRI and mammography to be the preferred strategy; starting at 25 prevented marginally more deaths, but with more testing and emotional stress

Getty Images

July 9, 2020 — Chest radiation is used to treat children with Hodgkin and non-Hodgkin lymphoma as well as lung metastases in various solid tumors. But radiation itself is a potential cancer risk, including an increased risk for breast cancer later in life. Girls receiving chest radiation for childhood cancer face a breast cancer risk as high as 30 percent by age 50.

What is the best strategy for catching these breast cancers early? Annual screening with mammography and breast MRI is recommended, but practices vary from location to location, and the benefits, harms, and costs are unclear. A new study led by Jennifer M. Yeh, Ph.D., in the Division of General Pediatrics at Boston Children's Hospital, used modeling to compare results of different approaches. The findings appear in the Annals of Internal Medicine.

"Randomized clinical trials are often thought of as the 'gold standard,' but they aren't always feasible for screening studies, especially in rare high risk groups such as survivors of childhood cancer," Yeh said. "However, those developing guidelines need information on the potential benefits and harms of screening. Decision modeling can provide important insight on these health outcomes."

Yeh, with collaborators across the country, used two breast cancer simulation models that were developed to guide screening recommendations for women who are not cancer survivors. The two models, part of the Cancer Intervention and Surveillance Modeling Network (CISNET), were adapted using information from the Childhood Cancer Survivor Study (CCSS). The CCSS is a cohort study on outcomes, including breast cancer, in more than 24,000 survivors of childhood and adolescent cancers diagnosed between 1970 and 1999.

The models evaluated the following annual screening strategies:

  • no screening
  • digital mammography and breast MRI, starting at age 25 (as per current recommendations of the Children's Oncology Group), 30 or 35
  • MRI only, starting at age 25, 30, or 35.

The models assumed that women who were screened continued to be screened until age 74, and that those diagnosed with breast cancer received the best therapy available at the time.

All annual screening approaches save lives

In the simulation, Yeh showed that without screening, childhood cancer survivors previously treated with chest radiation had a 10 to 11 percent lifetime risk of dying from breast cancer, as compared with a 2.5 percent risk among women in the general population.

Compared with no screening, all annual screening strategies prevented more than half of breast cancer deaths according to the models. A combined approach of both breast MRI and mammography, beginning at age 25, prevented the most deaths (an estimated 56 to 71 percent); MRI alone prevented slightly fewer (56 to 62 percent).

However, starting at age 25 also meant more screening tests, more false-positive findings, and more breast biopsies that turned out to be benign. For example, the researchers estimate that the average survivor screened with both MRI and mammography would have four to five false-positive screens and one to two breast biopsies over the course of her lifetime.

When the emotional stress and costs of additional screening and testing were factored into the analysis, starting at age 30 was the preferred strategy; relatively little was gained by starting at age 25. Either strategy reduced the risk of dying from breast cancer by at least half, with or without the addition of mammography to MRI.

Interpreting the findings

Lisa Diller, M.D., chief medical officer of the Dana-Farber/Boston Children's Cancer and Blood Disorders Center, is an expert in the care of childhood cancer survivors and a co-author of the study. "Breast cancer screening is one of the most important issues that oncologists should discuss with survivors of childhood chest radiation," Diller said. "Having these data informs discussions with young women who are facing screening at a very young age. It both reassures them that waiting until age 30 might be reasonable and impresses upon them that this screening could be life-saving."

One limitation of the study was that it used data from childhood cancer survivors diagnosed between 1970 and 1986. Since then, cancer treatment has changed, including decreased doses and improved delivery of radiation, and breast cancer monitoring now includes digital breast tomosynthesis, also known as 3D mammography.

"Our model-based findings suggest that even if the risk of breast cancer declines by half with more recent changes in radiation dose and delivery, early initiation of screening still remains favorable for these high-risk survivors," Yeh said. "Ensuring survivors are aware of and have access to screening can save lives."

For more information: www.childrenshospital.org/

Related Content

News | Radiation Therapy | May 06, 2021
May 6, 2021 — Individuals living with severe...
Research finds that a commonly used risk-prediction model for lung cancer does not accurately identify high-risk Black patients who could benefit from early screening

Getty Images

News | Lung Imaging | May 05, 2021
May 5, 2021 — Lung cancer is the third most common cance
The emergence of #therapeutic #radiopharmaceuticals and its adoption in #cancer care provide one more weapon in combating cancer

Getty Images

Feature | Radiation Oncology | May 04, 2021 | By Vinay Shivaprasad
The term nuclear medicine is associated with the diag
A 37-year-old woman developed a new, palpable left supraclavicular lymphadenopathy lump five days after her first dose of the Moderna COVID-19 vaccine in the left arm. On the day of vaccination, the patient was asymptomatic. This is an example of how the vaccine can mimic cancer and swollen lymph nodes. Image used with permission of RSNA.

A 37-year-old woman developed a new, palpable left supraclavicular lymphadenopathy lump five days after her first dose of the Moderna COVID-19 vaccine in the left arm. On the day of vaccination, the patient was asymptomatic. This is an example of how the vaccine can mimic cancer and swollen lymph nodes. Read more about this case study. Image used with permission of RSNA.

Feature | Coronavirus (COVID-19) | May 03, 2021 | By Dave Fornell, Editor
While the mass COVID-19 vaccinat
Despite receiving high radiation doses to their tumors, lung cancer patients treated with technique that spares a large part of the esophagus did not develop severe inflammation of the esophagus

Getty Images

News | Lung Imaging | April 30, 2021
April 30, 2021 — For many patients with localized lung cance...
#prostatecancer During the first wave of the corona pandemic, 36 percent fewer men were diagnosed with prostate cancer in Sweden than in previous years.

Getty Images

News | Prostate Cancer | April 30, 2021
April 30, 2021 — During the first wave of the corona pandemic, 36 percent fewer men were diagnosed with prostate canc
A 63-year-old multiple #myeloma patient, with skeletal pain. New #FDG avid axillary #lymphadenopathy 62 days (9 weeks) after second #mRNA #vaccination dose. Image used with permission of the Radiological Society of North America (#RSNA)

A 63-year-old multiple myeloma patient, with skeletal pain. New FDG avid axillary lymphadenopathy 62 days (9 weeks) after second mRNA vaccination dose. Image used with permission of the Radiological Society of North America (RSNA)

Feature | Coronavirus (COVID-19) | April 29, 2021 | By Melinda Taschetta-Millane